Loading...

Cymantic Medical

The Problem.
Up to 20% of biopsies and 30% of tumour resections in cancer care are unsuccessful or incomplete - a critical issue often unnoticed for days or even weeks. These undetected failures delay diagnosis and treatment, escalate healthcare costs, burden systems with repeat procedures, increase patient risks, and amplify clinician frustration.

There is a clear, urgent need for real-time technology to instantly verify procedural success, streamline care delivery, and significantly improve outcomes in cancer treatment.
The Mission.
We're pioneering the future of cancer diagnosis and treatment through cutting-edge computer vision technologies. Our solutions deliver real-time feedback on procedural accuracy, giving clinicians and surgeons the clarity and confidence to make better-informed decisions in the moment.

This not only boosts procedural success rates but can accelerate diagnosis and treatment timelines by months - dramatically reducing patient risks, healthcare costs, and clinician frustration caused by unnecessary repeat procedures.
Impact.

Patients

Patients will benefit from faster, more accurate diagnoses and treatments thanks to higher success rates in interventional procedures. By minimising, or even eliminating, the need for repeat procedures, our technology also reduces patients’ exposure to risks and potential complications, making their care safer and more efficient.

Healthcare Providers

Clinicians and surgeons gain real‑time guidance and confidence in their intra‑procedural decision‑making, streamlining workflows and reducing frustration.

Hospitals & Healthcare Systems

Hospitals and health systems can significantly lower operational strain and costs by cutting down on repeat procedures. Our solution optimizes resource utilisation - freeing up staff, equipment, and facility capacity while driving substantial savings and enabling higher patient throughput to serve more individuals without expanding infrastructure.
The Team.
Experienced medtech operator with experience spanning oncology research, clinical data, product development, business development, and commercialisation. MSc in Translational Oncology (Trinity College Dublin) and BioInnovate Fellow (Stanford Biodesign affiliate).
Stephen Geoghegan
Co-founder and CEO
BioInnovate Stanford Biodesign LSE SGS
Technology leader with deep expertise in computer vision and machine learning. Former AI lead at UnitedHealth Group and IBM Watson Health, and co-founder and CEO of Digifeye. PhD in Computer Vision and Machine Learning from Dublin City University.
Mark Hughes, PhD
Co-founder and CTO
IBM Watson Health UnitedHealth Group Fujifilm
Consultant oncologist with over 25 years of clinical experience. Trained at the Medical University of South Africa, Fellow of the College of Radiation Oncologists of South Africa, and BioInnovate Fellow (Stanford Biodesign affiliate).
Saleem Cassimjee, MD
Co-founder and CMO
BioInnovate Stanford Biodesign Health Service Executive
Experienced laboratory scientist and research engineer with a background spanning public diagnostic labs and industry R&D, including Charles River Laboratories and Reaction Biology Europe.
Birk Marold
Co-founder and CSO
Charles River Labs Jena University Hospital




Supported by

Address
Dublin, Ireland.
Scroll Up
 Previous  All works Next